Results

Total Results: 2,078 records

Showing results for "drugs".

441. Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/mcda-ijzerman.pdf
     January 01, 2011 - Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) Slide 1 Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) Maarten J…

442. Comparative Effectiveness of Treatments for Restless Legs Syndrome | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/restless-legs/research-protocol
     December 16, 2011 - Pharmacological treatment is generally reserved for patients with severe RLS. 11 The major classes of drugs … nicotine; antidepressants; antihistamines) †Adverse effects of treatments are specific to use of these drugs … We do not know the impact of long-term use of these drugs in children. … Neither do we know the risks/benefits of the drugs for older adults who take several medications for … All reported adverse reactions and effects including Augmentation (Harms specific to each class of drugs

443. Use of Observational Studies in Systematic Reviews of (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-observational-studies_methods.pdf
     June 01, 2010 - patients to be new users of the specific cohort-defining drug or new users of the entire class of drugs … biased observational studies require all patients in the cohort to be new users of the entire class of drugs … Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. … Drug class review: atypical antipsychotic drugs, Final report update 2. In: Helfand M, ed. … patients with schizophrenia initiating treatment with an atypical antipsychotic medication, which drugs

444. Calcineurin_Inhibitors_Protocol_FINAL_10-07-2014 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/calcineurin-inhibitor_research-protocol.pdf
     October 08, 2014 - amount of drug administered early or late post- transplant; 4) CNI avoidance, which substitutes other drugs … Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic … Pharmaceuticals. 2013;6(10):1170-94. Also available: http://dx.doi.org/10.3390/ph6101170. … relies on antibodies binding to specific antigens; frequently used to measure levels of therapeutic drugs … in a biologic sample Nephrotoxicity: exposure of the kidneys to poisonous (toxic) chemicals; many drugs

445. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/mindfulness-meditation-encompasses-a-range-of-meditation-techniques-that-have-been-increasingly-used-to-treat-behavioral-disorders-especially-those-associated-with-stress-some-of-these-were-previously-described-in-ahrq-public
     November 08, 2010 - no If yes, explain the specific technologies, devices, drugs, or interventions you would like to

446. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/with-the-rates-of-birth-by-cesarean-section-on-the-rise-what-factors-influence-and-which-have-the-greatest-impact-on-the-probability-of-delivery-by-cesarean-in-low-risk-women-which-interventions-are-most-effective-at-reducing
     January 01, 2010 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

447. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/comparative-effectiveness-of-conventional-computed-tomography-ct-multidetector-computed-tomography-mdct-ct-colonography-fludeoxyglucose-positron-emission-tomography-fdg-pet-or-fdg-petct-magnetic-resonance-imaging-mri-ultrasou
     December 27, 2011 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

448. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/1-does-mass-spectrometric-analysis-and-therapeutic-monitoring-of-tacrolimus-as-compared-with-immunoassay-analysis-and-therapeutic-monitoring-produce-a-better-organ-survival-rate-b-fewer-rejections-c-less-nephrotoxicity-andor-
     September 14, 2012 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

449. Data Points #14: Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/dcis-endocrine-therapy/research
     September 13, 2012 - Both drugs seem to have similar adherence problems despite distinct adverse effect profiles.

450. What is the comparative effectiveness of conventional CT, MDCT (including “virtual CT bronchoscopy”), PET/PET-CT, and MRI for the diagnosis or pretreatment staging of small cell and non-small cell lung cancer? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-is-the-comparative-effectiveness-of-conventional-ct-mdct-including-virtual-ct-bronchoscopy-petpet-ct-and-mri-for-the-diagnosis-or-pretreatment-staging-of-small-cell-and-non-small-cell-lung-cancer
     December 28, 2011 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

451. How can patients who have chronic diseases better prepare for critical illness and the end of life? Will a decision aid, using individualized estimates of outcomes, help shared decision making about advance care planning? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/how-can-patients-who-have-chronic-diseases-better-prepare-for-critical-illness-and-the-end-of-life-will-a-decision-aid-using-individualized-estimates-of-outcomes-help-shared-decision-making-about-advance-care-planning
     December 22, 2011 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

452. CER 173 Executive Summary: Diabetes Medications for Adults With Type 2 Diabetes: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_executive.pdf
     January 01, 2015 - medications have also emerged, which could change the balance of benefit and risk attributable to these drugs … While we did not combine studies in which individual drugs were found to be a clinical or statistical … Takeda Pharmaceuticals America. … Incretin mimetic drugs for type 2 diabetes: early communication - reports of possible increased risk … www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 25, 2015. 72.

453. Comparative Effectiveness of Second Generation Antidepressants in the Pharmacologic Treatment of Adult Depression—An Update to a 2007 Report. (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antidepressants-update_disposition-comments.pdf
     December 01, 2011 - would be drug vs drug and class vs class, and a separate one for comparing long and short-acting drugs … Hopefully not influenced by drug company marketing efforts to differentiate their drugs! … Basically, there are few differences between SGA drugs in the treatment of depression. … other second-generation antidepressants (Table 15)—and then listed alphabetically by the specific drugs … Section citalopram versus escitalopram (page 17, manuscript page 3): Although a difference between drugs

454. Crosscutting-Horizon-Scan-High-Impact-1512 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results The table below lists four topics for which (1) preliminary phase III data for drugs were … Now, Proteus is collaborating with Otsuka Pharmaceuticals Co., Ltd. … It differentiated 100% of multiple drugs and doses taken simultaneously by type and by dose. … Proteus is collaborating with Otsuka Pharmaceuticals Co., Ltd., (Tokyo, Japan) to integrate sensors

455. Identification and Treatment of Post-Acute Coronary Syndrome (ACS) Depression: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/acs-depression-research-protocol-amended.pdf
     February 15, 2017 - Appendix A: FDA Status and Warnings for Drugs … Vintage Pharmaceuticals,LLC, Huntsville, AL, 2006. 9. … Teva Pharmaceuticals USA, Inc. (per FDA), Horsham, PA, 2014. 19.

456. Nephropathy-Contrast-Induced Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/nephropathy-contrast-induced_research-protocol.pdf
     October 01, 2013 - converting-enzyme) inhibitors, angiotensin II receptor blockers, or non-steroidal anti- inflammatory drugs … Recent publications have questioned the role of N- acetylcysteine (NAC),8 withdrawal of nephrotoxic drugs … , ACE inhibitors, angiotensin II receptor blockers, diuretics, and non-steroidal anti-inflammatory drugs … we will explore the FDA AERS database for reported adverse events attributed to contrast media or drugs … Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.

457. Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/psoriasis-chronic/research-protocol
     September 27, 2011 - approaches to psoriasis treatment. 4,5,11 Biologic therapies for psoriasis use genetically engineered drugs … (Schwarz Pharma Manufacturing; OSI Pharmaceuticals Inc.) … disease has not adequately responded to methotrexate Neoral® (capsule, oral solution) Novartis Pharmaceuticals … USA (Barr Pharmaceuticals) Prednisone§ Generic formulations only (tablet, oral solution, intra-lesional … being developed for this indication Penicillin G benzathine‡ Bicillin L-A® (injectable) King Pharmaceuticals

458. Treatments for Fecal Incontinence: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/fecal-incontinence_clinician.pdf
     July 01, 2016 - Treatments typically follow a progression from less invasive nonsurgical interventions (dietary fiber, drugs … Nonsurgical treatments include dietary fiber supplementation, bowel schedules, stool-modifying drugs

459. A Rapid Evidence Review of Retention Strategies for Medications for Addiction Treatment (MAT) in Adults with Opioid Use Disorder | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/retention-strategies-opioid-use-disorder/rapid-protocol
     May 08, 2019 - Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs

460. Antipsychotics-Adults Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-adults_surveillance.pdf
     August 30, 2014 - The British Medical Journal 2 Clinical Neuropharmacology 2 Current Opinion in CPNS Investigational Drugs … adj3 bipolar).tw. 128 31 or/22-30 34791 32 or/21,31 127425 33 or/16,32 230151 34 exp Neuroleptic Drugs … Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments … participants) from Jan 1, 1980, to Nov 25, 2010, which compared any of the following pharmacological drugs … INTERPRETATION: Overall, antipsychotic drugs were significantly more effective than mood stabilisers